INDUSTRY NEWS Lonza Announces Worldwide, Exclusive Licensing and Supply Agreements with California Stem Cell Inc. Lonza Inc. has entered worldwide, exclusive licensing and supply agreements with California Stem Cell Inc. This collaboration makes novel pluripotent stem cell products readily available to researchers worldwide. [Lonza, Inc. Press Release] AssureImmune, Florida’s Premier Stem Cell Collection and Preservation Company, Merges with Banco De Cordón Umbilical, the Largest Cord Blood Bank in Latin America AssureImmune LLC announced their merger with Banco de Cordón Umbilical. [AssureImmune LLC Press Release] Connecticut Awards $9.8 Million in Stem Cell Research Grants Connecticut state has awarded $9.8 million in grants to support nearly two dozen stem cell research projects by scientists at the University of Connecticut and at Yale. [State of Connecticut Press Release] STEMCELL Technologies is Proud to Announce STEMcircles™, a Virus-Free Technology for Reprogramming Cells STEMCELL Technologies, Inc. announced that they have signed a licensing agreement with Stanford University for a virus-free technique used for the generation of induced pluripotent stem cells. [STEMCELL Technologies, Inc. Press Release] International Stem Cell Corporation’s Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office International Stem Cell Corporation announced that the United States Patent and Trademark Office has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic stem cells. [International Stem Cell Corporation Press Release] NIH Approves Advanced Cell Technology’s Stem Cell Line for Federal Funding Advanced Cell Technology, Inc. announced that human embryonic stem cell line MA135 was unanimously approved for federal funding at the 100th Meeting of the Advisory Committee to the Director National Institutes of Health (NIH). [Advanced Cell Technology, Inc. Press Release] Lorus Therapeutics Announces Presentation of Phase II Clinical Trial Data for LOR-2040 in Acute Myeloid Leukemia Lorus Therapeutics Inc. announced the presentation of Phase II clinical trial data for LOR-2040 (formerly known as GTI-2040) in combination with high dose cytarabine in the treatment of Acute Myeloid Leukemia. [Lorus Therapeutics Inc. Press Release] Cord Blood America Educating on Stem Cell Storage Cord Blood America, Inc. announced that Natalie Curry, the Company’s official spokesperson and medically saved by the first umbilical cord blood collection in the world, will discuss a wide range of topics about cord blood banking in a live webinar. [Cord Blood America, Inc. Press Release] Leading Cord Blood Experts Clarify Their Support of CORD:USE Family Cord Blood Bank CORD:USE’s Team of experts would like to clarify their specific support of CORD:USE’s family banking program, and to make it clear that their support of family cord blood banking is not a universal endorsement of all family banking enterprises or of unproven therapeutic uses of autologous cord blood cells. [PR Newswire] Companies Pledge to Make More Trial Data Public An international organization of pharmaceutical companies has adopted new guidelines governing the publication of clinical trial results. The policy calls for the industry to publish the results of late-stage, ‘phase 3′ clinical trials in peer-reviewed journals, regardless of the trials’ outcome. [NatureNews]
|